1. Home
  2. TRAK vs IMUX Comparison

TRAK vs IMUX Comparison

Compare TRAK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRAK

ReposiTrak Inc.

SELL

Current Price

$7.72

Market Cap

157.2M

Sector

Technology

ML Signal

SELL

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$8.03

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRAK
IMUX
Founded
1990
2016
Country
United States
United States
Employees
N/A
66
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.2M
155.8M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
TRAK
IMUX
Price
$7.72
$8.03
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $43.09
AVG Volume (30 Days)
72.6K
★ 405.8K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
★ 1.02%
N/A
EPS Growth
11.43
★ 38.00
EPS
★ 0.39
N/A
Revenue
★ $21,007,076.00
N/A
Revenue This Year
$9.50
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
$20.08
★ N/A
Revenue Growth
★ 4.84
N/A
52 Week Low
$6.94
$0.51
52 Week High
$15.80
$17.43

Technical Indicators

Market Signals
Indicator
TRAK
IMUX
Relative Strength Index (RSI) 35.77 29.56
Support Level $7.56 $0.83
Resistance Level $8.53 $15.82
Average True Range (ATR) 0.27 0.67
MACD -0.05 0.05
Stochastic Oscillator 9.90 18.10

Price Performance

Historical Comparison
TRAK
IMUX

About TRAK ReposiTrak Inc.

ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: